Accéder au contenu
Merck

Comparison of Immune Responses to Different Versions of VLP Associated Stabilized RSV Pre-Fusion F Protein.

Vaccines (2019-02-17)
Lori M Cullen, Madelyn R Schmidt, Gretel M Torres, Adam A Capoferri, Trudy G Morrison
RÉSUMÉ

Efforts to develop a vaccine for respiratory syncytial virus (RSV) have primarily focused on the RSV fusion protein. The pre-fusion conformation of this protein induces the most potent neutralizing antibodies and is the focus of recent efforts in vaccine development. Following the first identification of mutations in the RSV F protein (DS-Cav1 mutant protein) that stabilized the pre-fusion conformation, other mutant stabilized pre-fusion F proteins have been described. To determine if there are differences in alternate versions of stabilized pre-fusion F proteins, we explored the use, as vaccine candidates, of virus-like particles (VLPs) containing five different pre-fusion F proteins, including the DS-Cav1 protein. The expression of these five pre-F proteins, their assembly into VLPs, their pre-fusion conformation stability in VLPs, their reactivity with anti-F monoclonal antibodies, and their induction of immune responses after the immunization of mice, were characterized, comparing VLPs containing the DS-Cav1 pre-F protein with VLPs containing four alternative pre-fusion F proteins. The concentrations of anti-F IgG induced by each VLP that blocked the binding of prototype monoclonal antibodies using two different soluble pre-fusion F proteins as targets were measured. Our results indicate that both the conformation and immunogenicity of alternative VLP associated stabilized pre-fusion RSV F proteins are different from those of DS-Cav1 VLPs.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-RSV Antibody, fusion protein, all type A, B strains, clone 131-2A, clone 131-2A, Chemicon®, from mouse
Sigma-Aldrich
Anti-Mouse IgG (whole molecule)–Peroxidase antibody produced in sheep, affinity isolated antibody, buffered aqueous solution